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ABSTRACT  
Local long-term delivery of glial cell line derived neurotrophic factor (GDNF) from 
vitamin E/poly-lactic-co-glycolic acid microspheres (MSs) protects retinal ganglion 
cells in an animal model of glaucoma for up to 11 weeks. However, the 
pharmacokinetics of GDNF after intravitreal injection of MSs is not known. We 
evaluated the GDNF levels after a single intravitreal injection of GDNF/VitE MSs. 
Biodegradable MSs were prepared by the solid-oil-in-water emulsion-solvent 
evaporation technique and characterized. Rabbits received a single intravitreal 
injection (50 μL) of GDNF/VitE MSs (4%w/v; 24 right eyes; 74.85 ng GDNF), blank 
MSs (4%w/v; 24 left eyes), and balanced salt solution (4 eyes). Two controls eyes 
received no injections. At 24 hours, 1, 4, 6, 8, 12, 18, and 24 weeks after injection, 
the eyes were enucleated, and the intravitreal GDNF levels were quantified. 
Pharmacokinetic data were analysed according to non-compartmental model. 
Intraocular GDNF levels of 717.1 ± 145.1 pg/mL were observed at 24 hours for 
GDNF-loaded MSs, followed by a plateau (745.3 ± 25.5 pg/mL) until day 28. After 
that, a second plateau (17.4 ± 3.7 pg/mL) occurred from 8 to 24 weeks post-
injection, significantly higher than the basal levels. Eyes injected with GDNF/vitE 
and Blank-MSs did not show any abnormalities during the six-months follow up 
after administration. The single injection of GDNF/VitE MSs provided a sustained 
controlled release of the neurotrophic factor in a controlled fashion for up to six 
months. 
 
Keywords: Poly (lactic-co-glycolic acid) microspheres, protein delivery, vitamin E, 
glial cell line-derived neurotrophic factor (GDNF), pharmacokinetics, intravitreal 
injection.  
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1. Introduction  
Glaucoma is a group of neurodegenerative diseases in which the optic nerve is 
affected (Almasieh et al., 2012). Although high intraocular pressure (IOP) is the 
main risk factor, some patients have glaucoma even with normal tension values 
(Sommer, 1989). Neuronal damage can occur by different pathways, including 
excitotoxicity, protein misfolding, mitochondrial dysfunction, oxidative stress, 
inflammation, and neurotrophin deprivation among others. All of these mechanisms 
ultimately lead to programmed cell death with loss of retinal ganglion cells (RGCs) 
(Qu et al., 2010).  
Treatments directed to avoid irreversible damage of the neuronal cells are of 
great interest (Baltmr et al., 2010). Taking into account that glaucoma is a 
multifactorial disease, the most feasible pharmacological approach is directed 
toward the combination of several active substances with additive or synergistic 
effects. Based on this, the combination of a neurotrophic factor and an antioxidant 
agent would seem to be an optimal therapeutic strategy.  
Among the neurotrophic factors, the glial cell line-derived neurotrophic factor 
(GDNF) enhances the survival of dopaminergic and motor neurons in 
neurodegenerative diseases such as Parkinson and Alzheimer (Allen et al., 2013; 
Chen et al., 2000; Ghiso et al., 2013; Siegel and Chauhan, 2000). At the ocular 
level, exogenous, intravitreally injected GDNF has neuroprotective effect for RGCs, 
promoting the survival of axotomized cells (Cuenca et al., 2014; Klocker et al., 
1997). 
Antioxidants are also beneficial in neurodegenerative diseases in which 
neuronal death is associated with the damage of healthy neurons located in the 
proximity of massive releases of oxidative molecules (Engin et al., 2010; McManus 
et al., 2014; Mozaffarieh et al., 2008). Among the antioxidants, the free radical 
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scavenger vitamin E (α-tocopherol, VitE) produces results of great interest (Engin, 
2009). Furthermore, it has been proposed that VitE has antiproliferative properties 
that might reduce some of the side effects typically linked to repeated intravitreal 
injections such as proliferative vitreoretinopathy and retinal detachments (Larrosa 
et al., 1997).  
 
Due to the chronic nature of glaucoma, the applicability of GDNF and VitE in 
the neuroprotective therapy is totally linked to the development of effective 
administration devices that are able to supply therapeutic concentrations at the 
retina for extended periods of time (Checa-Casalengua et al., 2011). During the last 
two decades, the development of intraocular drug delivery systems (IODDS) is one 
of the main research areas for the treatment of chronic diseases affecting the back 
of the eye (Achouri et al., 2013; Goyal et al., 2014; Kompella et al., 2013). 
Depending on the size, IODDS are classified as nanoparticles (1-1000 nm), 
microparticles (1-1000 µm), and implants (>1 mm). Microparticles and implants 
have received a lot of interest because they can provide long-term delivery of the 
active substance. Microparticles have the advantage of easy administration 
because injection can be performed through conventional 25-34 gauge needles 
and thus avoiding surgery.  
Two structurally distinct types of microparticles are typically used to deliver the 
active substance: microcapsules and microspheres (MSs). Microcapsules are 
composed of a polymeric material that creates a reservoir in which the active 
substance is included. In contrast, MSs are composed of a polymer network that 
produces a matrix microsystem within which the active substance is dispersed 
(Herrero-Vanrell et al., 2014). Biodegradable MSs are an emerging therapeutic tool 
in the treatment of chronic intraocular pathologies because they are suitable for 
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administration close to the target site by periocular or intraocular routes. 
Additionally, they disappear from the site of administration after releasing the 
therapeutic molecule (Andres-Guerrero et al., 2015; Herrero-Vanrell and Refojo, 
2001; Herrero Vanrell and Refojo, 2001). Among the biodegradable polymers, poly-
lactic-co-glycolic acid (PLGA) has been the most employed, with one device 
already used in clinical practice (Ozurdex
®
). IODDS made of PLGA are gradually 
converted into CO2 and water in vivo and eliminated by ocular tissues (Makadia 
and Siegel, 2011). 
The potential inflammatory reactions and damage to retinas and vision function 
caused by intravitreally injected PLGA microspheres and their degradation products 
have been studied by several authors. They indicated that no inflammation nor cell 
toxicity in the retinas was triggered by the microspheres, the degraded products, or 
the changed microenvironments in the eyes. Ocular tissues show great tolerability 
and biocompatibility after the intravitreal administration of PLGA material (Abrego et 
al., 2015; Giordano et al., 1995; Rong et al., 2014; Veloso et al., 1997). However, 
an initial foreign body response after intravitreal injection can occurs under normal 
physiological conditions with no damage to the retina (Giordano et al., 1995). 
These same authors did not observe inflammatory signs 4 days after administration 
of microspheres and thereafter. 
PLGA-based GDNF-loaded MSs have been developed by different authors to 
provide slow drug release and long-lasting therapeutic effects (Andrieu-Soler et al., 
2005; Jiang et al., 2007; Ward et al., 2007). In a previous study, we developed 
GDNF/VitE-loaded MSs capable of providing in vitro release of the bioactive protein 
for up to 19 weeks. This formulation was intravitreally injected into rats with 
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elevated IOP, an animal model of glaucoma. It effectively protected the RGCs for at 
least 11 weeks (Checa-Casalengua et al., 2011).  
 
The injection frequency of the IODDS depends on the length of time that the 
active substance can be delivered after administration. For this reason, the 
evaluation of drug delivery systems designed to target retinal tissues or 
surrounding areas requires pharmacokinetic studies in the vitreous (Behar-Cohen 
et al., 2002; Fernandes-Cunha et al., 2014). Pharmacokinetic studies have been 
performed after injection of GDNF (bolus) in porcine eyes, and GDNF levels in the 
vitreous were quantified for seven days (Ejstrup et al., 2010). However, to the best 
of our knowledge, the study described here is the first to report the intravitreal 
pharmacokinetics of GDNF delivered from a microparticulate system over a long 
period (six months). The aim of the present study was to evaluate the GDNF levels 
after a single intravitreal injection of GDNF/VitE MSs. Pharmacokinetic study were 
done in rabbits, and data were analysed using non-compartmental treatment. 
 
2. Materials and methods 
2.1. Materials 
GDNF and the enzyme-linked immunosorbant assay (ELISA) kit for GDNF 
quantification were supplied by R&D Systems (Minneapolis, MN, USA). PLGA ratio 
50:50 (Resomer®503) was purchased from Boehringer Ingelheim Pharma GmbH & 
Co. (Ingelheim, Germany). Polyvinyl alcohol 72,000 g/mol (PVA) was obtained from 
Merck KGaA (Darmstadt, Germany). N-(tetramethylrhodamine-6-thiocarbamoyl)-
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (TRITC-DHPE) was 
purchased from Invitrogen (Carlsbad, CA, USA). VitE (α-tocopherol acetate), 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
7 
bovine serum albumin (BSA), and human serum albumin fluorescein isothiocyanate 
(HSA-FITC) were obtained from Sigma-Aldrich (Schnelldorf, Germany).  
 
2.2. Microsphere elaboration 
GDNF/VitE-loaded PLGA MSs were elaborated using a solid-in-oil-in-water 
(S/O/W) emulsion solvent evaporation technique previously developed by our 
group (Checa-Casalengua et al., 2011). Briefly, 20 g of GDNF was suspended in 
20 L VitE by gentle sonication at low temperature (0ºC) (Sonicator XL, Head 
Systems, Farmingdale, New York, USA) for 30 sec. The suspension was then 
mixed with 1 mL of PLGA solution in methylene chloride (20% w/v). This organic 
phase was emulsified with 5 mL of PVA MilliQ
® 
water solution (2% w/v) in a 
homogenizer (Polytron
®
 RECO, Kinematica GmbH PT 3000, Lucerna, Switzerland) 
at 5,000 rpm for 1 min. The emulsion was subsequently poured onto 100 mL of an 
aqueous PVA solution (0.1%) and kept under constant stirring for 3 h to allow 
organic solvent evaporation. Once formed, the MSs were washed, filtered, freeze-
dried, and kept at -20 ºC under dry conditions until used.  
 
2.3. Microsphere characterization  
2.3.1. Production yield percentage (PY%)  
The PY% of each formulation was calculated as the percentage of MSs weight 
divided by the total amount of the components (polymer, drug, and VitE) initially 
used in the formulation process.  
100
VitE andprotein  polymer, ofamount  total
esmicrospher ofweight 
=PY%   
 
2.3.2. Mean particle size and particle size distribution  
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The mean particle size and particle size distribution were measured by light 
scattering in a Microtrac
®
 S3500 Series Particle Size Analyzer (Montgomeryville, 
PA, USA).  
 
2.3.3. Morphological evaluation  
The external morphology of freeze-dried MSs was evaluated by scanning 
electron microscopy (Jeol, JSM-6335F, Tokyo, Japan). Samples were gold sputter-
coated prior to observation.  
2.3.4. Protein and additive distribution in PLGA MSs  
A model labelled-protein, HSA-FITC, was encapsulated in the same conditions 
described for GDNF (Checa-Casalengua et al., 2011). Combinations of the additive 
VitE with small proportions (6 μg) of the fluorescent lipid dye TRITC-DHPE (0.5 
mg/mL in CH2Cl2) were also included in the Oil-phase. Samples of this formulation 
were placed in release media for 24 h (see in vitro release studies). Freshly 
prepared MSs samples (time 0 h) and samples taken 24 h after release were 
observed by confocal microscopy (Leica TCS SP2, Leica Microsystems Heidelberg 
GmbH, Germany). 
 
2.3.5. Encapsulation efficiency  
To determine the encapsulation efficiency, 5 mg of MSs were dissolved in 0.7 
mL of methylene chloride. Then, the same volume of the reactive diluent composed 
of phosphate buffered saline, pH 7.4, and 1% BSA provided in the ELISA Kit 
(DY995, R&D System) was added. After vigorous mixing, the heterogeneous 
system was centrifuged (12,000 rpm, 15 min, 4°C) and the aqueous phase 
extracted. This liquid/liquid extraction was repeated four times to recover all of the 
encapsulated protein. Following the extraction, GDNF immunoassays were 
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performed in triplicate.  
 
2.3.6. In vitro release studies  
To determine the rate of GDNF release from the MSs, duplicate samples of 
GDNF/VitE-loaded MSs (5 mg) were suspended in a release medium composed of 
1.5 mL of phosphate buffered saline (pH 7.4 isotonic with NaCl) containing 1% BSA 
and 0.02% sodium azide. LoBind Eppendorf® vials were used in all cases. 
Samples were maintained under a constant agitation speed of 100 rpm (Clifton 
Shaking Bath NE5, Nikel Electro Ldt, Avon, UK) at 37ºC. At 1 h, 24 h, and once a 
week until the end of the assay (24 weeks), the MSs suspension were gently 
centrifuged (5,000 rpm for 5 min), and the supernatants were recovered and 
replaced by the same volume of fresh medium. GDNF in the supernatant aliquots 
were then assayed by ELISA as described above. When necessary, the aliquots 
were diluted with the reactive diluent. 
 
2.4. In vivo assays 
2.4.1. Animals 
All of the animals were handled according to the Spanish Policy for Animal 
Protection RD1201/05, which meets the European Union Directive 86/609/EEC. 
Animal assays were carried out in compliance with the ARVO Statement for the use 
of animals in experimental procedures and other scientific purposes. All methods 
were carried out according to the Project License PI12/02285 approved by the in-
house Ethics Committee for Animal Experiments for the University of Zaragoza 
(Spain).  
Investigations were performed in 27 adult female New Zealand albino rabbits 
(2 – 3.5 Kg, Servicio de Apoyo a la Experimentación Animal [SAEA], Zaragoza 
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University, Zaragoza, Spain). The animals were housed singly in standard cages, in 
a light-controlled room (12 h/12 h dark/light cycle) at 20 ± 2º C with a relative 
humidity of 40 - 70%. Diet and water were available ad libitum and clinical 
observations were performed daily.  
 
2.4.2. Intravitreal injections 
All injections were performed under general anaesthesia and aseptic 
conditions. The animals were anaesthetized intramuscularly with a mixture of 
ketamine hydrochloride (25 mg/Kg; Ketolar 50
®
, Pfizer, Madrid, Spain) and 
medetomidine (0.5 mg/Kg; Domtor®, Esteve, Madrid, Spain). Topical anaesthesia 
was achieved by eyedrops with 1 mg/mL tetracaine chlorhydrate and 4 mg/mL 
oxibuprocaine chlorhydrate (Colircusí Anestésico Doble
®
, Alcon Cusí SA, 
Barcelona, Spain). Povidone-iodine solution (5%) was applied for ocular surface 
antisepsis before and immediately after the intravitreal injection. All of the injections 
were performed by the same ophthalmologist. Before the injection, aqueous 
humour paracentesis of 0.03-0.05 mL approximately with a 30-guage needle was 
performed to prevent backflow of MSs and an increase of IOP (Aref., 2012).  
The animals were randomized into 9 groups (Groups 1 – 8, n = 3 each; Group 
9, n = 2) and a single control rabbit (Table 1). During the anaesthesia, the right 
eyes of the 24 rabbits in Groups 1 – 8 were injected intravitreally with GDNF/VitE-
loaded PLGA MSs. The left eyes of the same rabbits were injected with non loaded 
PLGA MSs (Blank-MSs). In Group 9, all four eyes were injected with 50 μL of 
balanced salt solution vehicle (BSS
®
; Alcon Laboratories, Inc.; Fort Worth, TX, 
USA). The control rabbit received no injection, and both eyes were enucleated to 
compare the basal concentration of GDNF with rabbits that received the intravitreal 
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injection. The bilateral injections were done to reduce the number of animals used 
for the study.  
To ensure a homogeneous dispersion of MSs in the injection, 4% (w/v) 
suspensions of the MSs were prepared in BSS and briefly vortexed immediately 
before each injection. A 50 μL-volume of suspension was then injected intravitreally 
with a 25-gauge needle placed in the superior-temporal quadrant of the eye. 
According to the encapsulation efficiency of GDNF in the MSs, the dose 
administered was 74.85 ng of GDNF. Under surgical microscope visualization, the 
needle tip was directed to the centre of the vitreous body, about 3-5 mm posterior 
to the limbus. At post-injection time points of 24 h and at 1, 4, 6, 8, 12, 18, and 24 
weeks, the animals were humanely killed by rapid intravenous bolus injection of 30 
mg/Kg sodium pentobarbital, and the eyes were enucleated and immediately 
dissected. The entire vitreous body was peeled from the everted globe and frozen 
at -20°C. The intravitreal concentration of GDNF was determined by ELISA as 
described below. 
 
2.4.3. General health and clinical findings 
IOP measurements for all animals were performed using a rebound tonometer 
(TonoVet
®
 TV01, iCare Finland OY, Vantaa, Finland). Pressures were measured 
before and at 24 h and at 1, 4, 6, 8, 12, 18, and 24 weeks after the intravitreal 
injection. The ocular health status was observed over the study period by slit-lamp 
examination of the ocular anterior segments and by indirect fundus 
ophthalmoscopy through dilated pupils with a 20-diopter aspheric lens.  
 
2.4.4. Quantification of vitreous samples by ELISA 
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All vitreous samples were sonicated (Sonicator XL) at a low temperature for 1 min. 
Afterwards, the samples were centrifuged at 12,000 rpm for 10 min. The GDNF 
content in the supernatant was determined by ELISA (DuoSet® ELISA 
Development System, R&D Systems Inc.). The assays were done according to the 
manufacturer’s instructions on tissue culture treated 96-well plates (Costar® 3599, 
Corning Inc., Corning, NY, USA), and the absorption at 450 nm was read in a multi-
detection microplate reader (BioTek® Synergy™ HT, BioTek Instruments, Inc., 
Friedrichshall, Germany). Experimental samples were tested in triplicate, and 
experimental GNDF concentrations were calculated using the average absorbance 
of the three readings plotted against the standard curve. Two anchoring points 
below the routine limit of 15.6 pg/mL (7.8 and 3.9 pg/mL) were used for GDNF 
quantification in vitreous (Smolec et al., 2005). The same restriction in the detection 
limit fixed for lower limit of quantification and upper limit of quantification (back 
calculated concentration within 25 % of nominal value) was also demanded for this 
anchoring point for acceptance (EMA guideline on bioanalytical method validation., 
2012). 
  
2.4.5. Pharmacokinetics and statistical analysis 
All values were expressed as means ± standard deviations except the mean 
concentration values from vitreous samples that were graphically represented by 
using the standard error of the mean. The data were analyzed by Statgraphics 
software (StatPoint Technologies, Inc., Warrenton, VA, USA). A p-value of less 
than 0.05 was considered to be statistically significant. 
The mean intravitreal concentrations (Cvitreous) of samples collected after 
injection of GDNF/VitE MSs were used to perform the pharmacokinetic analysis. 
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2.4.5.1. Non-compartmental analysis 
The primary pharmacokinetic parameter “apparent vitreous clearance” 
(Clapp(vitreous))  was calculated using the general equation:  
                                 Clapp(vitreous)/Fr= 
 
where the experimental area under curve (AUC) was estimated by a linear-
trapezoidal method with the data collected during the 24 weeks of the in vivo study. 
“Fr” is a correction factor that does not represent bioavailability (considered 100 %) 
in this case, but the fraction dose released during 24 weeks of the in vitro study. 
The profile of the intravitreal concentrations showed two consecutive plateaus: 
the first one from 24 h to 4 weeks (Stage 1) and the second one from 8 to 24 weeks 
(Stage 2). Both exhibiting zero-order release kinetics. The steady state 
concentrations (Css1 and Css2) were calculated from the mean values of intravitreal 
concentrations corresponding to each stage.   
The release rate constants at both stages (K01app and K02app), following the zero-
order kinetics, were related to Css1 and Css2 according to the following equation: 
K0app = Clapp(vitreous)/Fr x Css. 
The K0 data for both stages might be considered only as approximate values, 
according to the limitations offered by clearance calculations, that is why have 
named them “apparent” release constant.  
The initial burst in vivo was estimated as follows: 
Initial burst = Vitreal concentration at 24h x Anatomical volume of rabbit vitreous. 
dose 
AUC 
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Where the anatomical volume of rabbit vitreous was taken as the value reported by 
Del Amo et al. for albino rabbits (Del Amo et al., 2015). It is necessary to point out 
that it is an inaccurate estimation, so there is no guarantee that the true peak 
concentration occurs at 24 h, the first sampling point, and the apparent volume of 
distribution might be higher than the anatomical volume. 
3. Results  
3.1. Microsphere elaboration and characterization 
The production yield for microencapsulation of GDNF/VitE MSs was 79.1 ± 
7.8% and the mean particle size was 19.1 ± 9.4 μm (Fig. 1, inset). The particles 
were spherical and had a high number of small pores on the surface (Fig. 1).  
Confocal microscopy showed the initial distribution of HSA-FITC and VitE mixed 
with TRITC-DHPE in the MSs and the distribution after 24 h in the release medium 
(Fig. 2). Initially, the HSA-FITC was located mostly near the surface of the particles, 
and VitE (mixed with TRITC-DHPE during the microencapsulation procedure) was 
homogeneously distributed in the polymeric matrix. After 24 h in the release 
medium, the intensity and depth of the HSA-FITC fluorescent ring was diminished 
but still present. This fact can be related with an initial important release of the 
protein in the first 24 h, as occurs with GDNF. However, beanching phenomena 
cannot be discarded.  
 
3.2. Encapsulation efficiency and in vitro release of GDNF 
 The GDNF/VitE formulation encapsulated 37.43 ± 0.74 ng/mg MSs of GDNF 
for an encapsulation efficiency of 42.74 ± 1.66%. A sustained release of GDNF has 
been observed (Fig. 3). During the first 24 h, 49.3% of the GDNF incorporated in 
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the MSs was delivered from the GDNF/VitE formulation. After this initial GDNF 
burst, there was a sequence of fast and slow release steps (Fig. 3). First, there was 
a fast protein delivery for 7 days. After that, the release rate was 48 pg GDNF/mg 
MSs/day during the next 35 days (from 7
th
 to 42
nd
 day). After a fast delivery within 7 
and 8 weeks (773 pg GDNF/mg MSs/day), the GDNF/VitE formulation released the 
GDNF in a sustained fashion for 42 days, from day 56 to day 98, with a release rate 
of 89 pg GDNF/mg MSs/day. From day 98 to 140 a release rate of 30 pg GDNF/mg 
MSs/day was denoted and finally, also a sustained release at a rate of 12 pg 
GDNF/mg MSs/day was observed until the end of the assay (day 168). At the end 
of the in vitro release study, the remaining GDNF content was more than 4% of the 
originally encapsulated agent. 
 
3.3. In vivo assays 
3.3.1. General health and clinical findings 
IOP and clinical signs of ocular inflammation such as abnormalities in the 
cornea and inflammation in the anterior and posterior segments were evaluated 
before and after treatments. The eyes injected with the GDNF/VitE-loaded and 
blank MSs did not show any abnormalities during the six-month follow up after 
administration. In all animals, the corneas remained clear, and there were no 
observable anterior chamber reactions or iris abnormalities. Also, the posterior 
segments, particularly the retina and optic nerves, were free of any inflammatory 
response. Four eyes developed cataracts in the posterior lens capsule, probably 
due to trauma associated with the injection itself. Moreover, the IOPs were within 
normal limits over the study period, and no case exceeded 14 mmHg. There were 
no significant differences in IOP between eyes injected with GDNF/VitE or blank 
MSs (Fig. 4). 
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3.3.2. Ocular pharmacokinetics of GDNF after intravitreal 
administration 
3.3.2.1. Vitreous levels of GDNF 
The intravitreal GDNF concentrations after administration of 2 mg of 
GDNF/VitE and 2 mg of blank MSs are presented in Fig. 5. Consistent with the 
release burst observed in vitro, 24 h after injection of the GDNF-loaded particles, 
intravitreal GDNF concentrations reached 717.1 ± 145.1 pg/mL. At this initial point 
the injection of non-loaded MSs caused the basal levels of GDNF to increase to 
10.2 ± 4.0 pg/mL. compared with the vitreous measured from non-treated animals 
(< 3.9 pg/mL, detection limit). During the following four weeks, GDNF levels were 
maintained at 745.3 ± 25.5 pg/mL (Css1) in eyes receiving GDNF-MSs, which was 
almost one hundred fold higher than the values in eyes receiving blank MSs, 7.8 ± 
2.5 pg/mL. At six weeks post-GDNF MSs injection, the intravitreal GDNF 
concentration was 5.9 ± 0.6 pg/mL. After that, the GDNF concentration was 
maintained at 17.4 ± 3.7 pg/mL (Css2) from the 8
th
 week to the end of the assay 
(24
th
 week). GDNF quantification in animals receiving blank microspheres were 
over the detection limit during the first 4 weeks of the in vivo study. 
 
3.3.2.2. Pharmacokinetic parameters 
Based on the determinations of GDNF concentrations in the vitreous over the 
course of the study, the pharmacokinetic parameters for the non-compartmental 
analysis were determined (Table 2). 
  
3.3.2.3. In vivo GDNF release from the MSs 
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Around 911 pg of the administered GDNF was initially released as a burst from 
the MSs during the first 24 hours. After that, GDNF was released during the 
following 4 weeks at a constant rate of 2 ng/day (Stage 1). The remaining 
neurotrophic factor was released at a constant rate of 46 pg/day until the end of the 
assay (Stage 2). These values were calculated considering that Clapp(vitreous)/Fr 
describes the true vitreal clearance. 
 
4. Discussion 
Most neurodegenerative diseases induce irreversible loss of function in 
patients (Murakami et al., 2013). GDNF has a neuroprotective effect in delaying the 
degenerative process of retinal pathologies (Cuenca et al., 2014; Klocker et al., 
1997). This effect occurs even at low concentrations if maintained for long periods 
of time. In fact, we have recently shown that 0.8 pg/day GDNF delivered by PLGA 
MSs resulted in RGC and axonal survival 11 weeks after injection in rats with 
induced glaucoma (Checa-Casalengua et al., 2011). These promising results 
indicated that biodegradable microparticulate systems can be considered as 
therapeutic tools in the treatment of chronic intraocular diseases in which the 
degeneration occurs slowly (Herrero-Vanrell et al., 2014). Furthermore, as the 
active substance is released close to the target site for long periods of time, the 
number of repeated applications can be significantly reduced (Herrero-Vanrell and 
Refojo, 2001).  
In the present work, we prepared a MSs formulation with GDNF and VitE. We 
have selected PLGA as biocompatible and biodegradable polymer to control the 
release of the neurotrophic factor. This polymer undergoes homogeneous 
hydrolytic degradation that promotes the formation of pores and cavities (Wang et 
al., 2010) releasing the active compound from the PLGA matrix through diffusion 
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(Aubert-Pouessel et al., 2004). The particle size of about 19 μm and the spherical 
shape made this formulation suitable for being injected as a suspension through 
small needles (30 – 32 guage) used for intravitreal administration (Herrero-Vanrell 
and Refojo, 2001). Scanning electron microscopy images showed the presence of 
pores in the MSs surfaces. This fact has been previously reported, and it is 
attributed to the rapid removal of organic solvent during the elaboration of the 
formulation (Al Haushey et al., 2007) and also to the presence of the oily additive 
VitE in the formulation (Checa-Casalengua et al., 2011).  
One of the most remarkable technological aspect in the MSs formulation 
reported in this work is the presence of an oil (VitE) that allows the incorporation of 
the GDNF as a solid in the MSs. This fact helps to maintain the integrity of the 
neurotrophic factor (Checa-Casalengua et al., 2012) and extend the release of the 
active substance compared with the MSs without additive (data non shown). From 
a pharmacological point of view, the antioxidant properties of VitE presumably 
might help to reduce the oxidative stress associated with glaucomatous optic 
neuropathy (Mozaffarieh et al., 2008).  
For confocal studies, we used HSA-FITC to determine protein distribution in 
PLGA matrix instead of GDNF. Unfortunately to our knowledge, it does not exist 
GDNF fluorescently labelled commercially available. Although GDNF and HSA are 
two proteins with different molecular weight, it could be assumed that the handling 
procedures such as sonication in VitE and emulsification in homogenizer might 
have more influence in the final distribution of the protein in the polymeric matrix 
than its molecular weight, considering that the protein is always in its solid state 
(Checa-Casalengua et al., 2011). According to the confocal microscopy findings, 
the protein distribution among the polymeric matrix, seems to condition the release 
behaviour.  
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Although the main anatomical and physiological parameters in humans and 
rabbits´ eyes show small differences, the pharmacokinetic parameters (clearance, 
volume of distribution and half-life) in the human and rabbit eye have good 
correlation and comparable absolute values. So, reliable rabbit-to-man translation 
of ITV pharmacokinetics should be feasible. For this reason, for pharmacokinetic 
studies, we selected rabbits (Del Amo et al., 2015; Los., 2008; Zahn et al., 2010; 
Bösze and Houdebine., 2006). We have intravitreally injected 50 μL-volume of 4 % 
w/v homogeneous suspension of microspheres which lead to a concentration of 
microspheres in the rabbit vitreous of 1.6 mg/mL according to a theoretical rabbit 
vitreous volume of 1.27 mL (del Amo et al., 2015). In other works, higher amount of 
PLGA microspheres were evaluated. For example, Giordano et al used amounts of 
microspheres (2.5 mg, microspheres vitreous concentrations of 1.97 mg/mL) in 
order to study the biodegradation and the tissue reaction of microspheres 
intravitreally injected in rabbits. They conclude that these PLGA microspheres were 
not toxic to ocular tissues (Giordano et al., 1995). In this line, Rong et al, have 
explored the eye biocompatibility and the safety of PLGA/PLA microspheres 
through intravitreal injection in New Zealand rabbits. Intravitreal administration of 
different doses of PLGA/PLA microspheres were evaluated: low (2.5 mg, 
microspheres vitreous concentrations of 1.97 mg/mL), medium (5 mg, 
microspheres vitreous concentrations of 3.94 mg/mL), or high (10 mg, 
microspheres vitreous concentrations of 7.81 mg/mL). Examinations were 
performed by evaluating retinal histological and functional changes up to 12 weeks 
post administration. This study demonstrated that intravitreal injection of a 
PLGA/PLA microspheres drug delivery system resulted biocompatible and safe 
(Rong et al., 2014). In the present work a small amount of microspheres was used 
in an attempt to combine good tolerance at long term with the need of detectable 
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GDNF concentrations in the vitreous during 24-weeks study. However, this amount 
can be increased according to patient’s needs 
In order to reduce the number of animals used for the study and due to 
protocol ethical factors, bilateral injections were done. As microspheres are locally 
injected in the vitreous, the GDNF released from them might be confined to the 
treated eye. Although it is theoretically possible that part of the active substance 
could reach the blood stream by crossing the blood-retinal barrier, this 
phenomenon depends mainly on the compound molecular weight and also on their 
concentration. The access of the active compound to the contralateral eye in the 
present work was limited by the slow release of GDNF from the microspheres as 
well as by its molecular weight (23,000 g/mol). In fact, other authors such as Ward 
et al (2007) or Ejstrup et al., (2010), have also used the contralateral eye as 
negative control.  
It has been postulated that the intravitreal injection itself is sufficient to cause 
substantial reactive changes in Müller cells and microglia throughout the entire 
retina at least for the first 24 hours (Seitz et al., 2014). Furthermore, attending to 
Igarashi et al, Müller cells and astrocytes express GDNF (Igarashi et al., 2000). It is 
then reasonable to hypothesize that, if activity of Müller cells and astrocytes 
increases, the expression of GDNF may also increases. To evaluate this point 
measurement of GDNF in vitreous injected only with BSS were performed. 
Although detectable, the analytical data resulted under the quantification limit (<3.9 
pg/mL) and by hence not significant in this case. Furthermore, we also measured 
the GDNF vitreous concentration in control eyes injected with blank microspheres. 
In this sense we were able to observe an increment in this control group during the 
first 4 weeks of the study (values beyond 3.9 pg/mL). This low but detectable 
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increment in endogenous might be due to the presence of microspheres 
themselves in the vitreous. 
MSs act like reservoirs in the vitreous, and the active substance delivered from 
the particles diffuses in the vitreous gel, as previously reported by Veloso et al. 
(Veloso et al., 1997). After that, the released molecules are distributed and 
eliminated. These events largely depend on the physicochemical properties of the 
substance and the tendency of GDNF to diffuse to the retina (Ejstrup, R., 2010). 
According to our results, GDNF/VitE formulation released the neurotrophic factor 
into the vitreous body at least for six months following intravitreal injection. 
It has been reported that PLGA MSs tend to aggregate after intravitreal 
injection (Barcia et al., 2009) which surely might influence in the release profile of 
the protein. Although in vitro, also certain tendency of aggregation can be also 
observed after several weeks of incubation in release media (Checa-Casalengua et 
al., 2011), these two phenomena cannot easily compared. Furthermore, while in 
the in vitro study the released protein is maintained in the release media until 
quantification, in vivo occurs just the opposite, and the released protein can diffuse 
to the tissues (retina in this case) and/or is degraded in the vitreous once released. 
This could explain why the sequence of rapid then slow GDNF release steps in 
vitro was not correlated with the in vivo GDNF release behaviour postulated after 
pharmacokinetic data treatments. In vivo, the fast release of GDNF occurring at 
stage 1 can be explained for the diffusion of the active substance through the pores 
of the polymeric matrix, followed by a slow release due to polymeric matrix bulk 
erosion (stage 2). The in vivo assay was performed over a period of 168 days (24 
weeks). At that time point, according to pharmacokinetic data, not all of the loaded 
GDNF had been released from MSs. It is possible that the remaining GDNF could 
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have resulted in an extended second stage, although this should be experimentally 
confirmed.  
Because of the potency and mechanism of action, the concentrations of 
neurotrophic factors needed to provide neuroprotection are low (Brodski et al., 
2002). In vitro, the EC50 of GDNF that enhances dopaminergic neuron survival is 40 
pg/mL (Lin et al., 1993). This estimated minimal concentration could be previously 
considered by other authors as the therapeutic concentration able to promote RGC 
rescue in a porcine elevated IOP glaucoma model (Ejstrup et al., 2010). These 
authors found that after the administration of 100 ng of GDNF in solution (bolus) 
into the porcine eye (vitreous volume 2.2 mL), values of the neurotrophic factor 
higher than the estimated minimal concentration were maintained for 15 days. 
However, other authors have observed neuroprotective effects for GDNF 
concentration in the vitreous that were lower than the estimated minimal value 
when it is continuously released from MSs. In fact, Ward et al. showed an 
increment in RGC survival in DBA/2J mice (vitreous volume 0.005 mL) after 
repeated injections of GDNF-loaded MSs with a total theoretical release of GDNF 
of 0.707 ng in two months (Ward et al., 2007). The same formulation of GDNF-
particles was also neuroprotective in a rat glaucoma model (vitreous volume 0.05 
mL) with chronically elevated IOP (Jiang et al., 2007). MSs (0.05 mg) containing 
GDNF were injected into the vitreous. After nine weeks, the theoretical total release 
of GDNF was 1.77 ng, which provided RGC protection. Kyhn et al. demonstrated 
also RGC protection for 6 weeks in a pig model of acute retinal ischemia after 
administration of 2 mg of particles that provided a total GDNF release of 70.8 ng 
(Kyhn et al., 2009). Finally, we previously demonstrated that even as little as 0.64 
ng of GDNF administered by GDNF/VitE PLGA MSs in the chronic hypertension rat 
model of glaucoma protected RGCs for at least 11 weeks (Checa-Casalengua et 
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al., 2011). In fact, we postulated that in vitro release rates of GDNF as low as 0.8 
pg/day could be neuroprotective (Checa-Casalengua et al., 2011).  
Unfortunately, no GDNF quantification was performed in any of the in vivo 
studies. In the present study, we administered a total GDNF dose of 74.85 ng, 
which produced a high GDNF concentration, about 745 pg/mL. This was more than 
18 fold higher than the estimated minimal threshold of 40 pg/mL that was detected 
in the rabbit vitreous for the first 28 days. According to our pharmacokinetic 
analysis, the in vivo release of the neurotrophic factor is consistent in a zero-order 
kinetic process that is followed by a predominant elimination step between weeks 4 
and 6. After that, a second zero-order kinetic phase resulted in a low but sustained 
GDNF concentration, around 18 pg/mL and an estimated in vivo release rate of 
50.2 pg/day, from day 56 until the end of the experiment.  
Considering that there is no in vivo data concerning the therapeutic 
concentration of GDNF (Ward et al., 2007), it is difficult to estimate the optimal 
dosage, especially if it is released from MSs like those that were neuroprotective for 
11 weeks in a glaucoma model (Checa-Casalengua et al., 2011). It is then rational 
to consider that our MSs might be neuroprotective not only for the first 28 days, 
with GDNF values in vivo ˃ 40 pg/mL, but also for at least six months. Extended 
activity in vivo studies should be made to confirm this hypothesis. 
 
5. Conclusions  
The method described in this work allowed for the encapsulation and controlled 
in vitro release of GDNF for at least 24 weeks. After a single injection of the novel 
formulation GDNF/VitE into the rabbit vitreous, GDNF was released in a sustained 
fashion for at least six months.  
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ABSTRACT  
Local long-term delivery of glial cell line derived neurotrophic factor (GDNF) from 
vitamin E/poly-lactic-co-glycolic acid microspheres (MSs) protects retinal ganglion 
cells in an animal model of glaucoma for up to 11 weeks. However, the 
pharmacokinetics of GDNF after intravitreal injection of MSs is not known. We 
evaluated the GDNF levels after a single intravitreal injection of GDNF/VitE MSs. 
Biodegradable MSs were prepared by the solid-oil-in-water emulsion-solvent 
evaporation technique and characterized. Rabbits received a single intravitreal 
injection (50 μL) of GDNF/VitE MSs (4%w/v; 24 right eyes; 74.85 ng GDNF), blank 
MSs (4%w/v; 24 left eyes), and balanced salt solution (4 eyes). Two controls eyes 
received no injections. At 24 hours, 1, 4, 6, 8, 12, 18, and 24 weeks after injection, 
the eyes were enucleated, and the intravitreal GDNF levels were quantified. 
Pharmacokinetic data were analysed according to non-compartmental model. 
Intraocular GDNF levels of 717.1 ± 145.1 pg/mL were observed at 24 hours for 
GDNF-loaded MSs, followed by a plateau (745.3 ± 25.5 pg/mL) until day 28. After 
that, a second plateau (17.4 ± 3.7 pg/mL) occurred from 8 to 24 weeks post-
injection, significantly higher than the basal levels. Eyes injected with GDNF/vitE 
and Blank-MSs did not show any abnormalities during the six-months follow up 
after administration. The single injection of GDNF/VitE MSs provided a sustained 
controlled release of the neurotrophic factor in a controlled fashion for up to six 
months. 
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Figures  
Fig. 1 
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Fig. 3  
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Fig. 4 
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Fig. 5 
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Captions  
 
Fig. 1 Scanning electron microscopy images of GDNF/Vit E microspheres. Inset: 
Particle size distribution. 
 
Fig. 2 Confocal microscopy images of HSA-FITC and VitE-TRITC-DHPE 
distribution in PLGA microspheres at t = 0 h and t = 24 h after incubation in the 
release medium. The combination images were created by merging the HSA-FITC 
images with the VITE-TRITC-DHPE images. 
 
Fig. 3 (A) Cumulative in vitro release of GDNF from GDNF/Vit E microspheres 
(ng/mg MSs) over 168 days (six months) from the GDNF/VitE MSs. Release media: 
PBS (pH 7.4), 1% BSA and 0.02% Na azide. Inset: Cumulative release of GDNF 
from the GDNF/VitE formulation from day 140 to day 168. (B) Schematic 
representation of the release rate for formulation GDNF/VitE for 168 days. 
 
Fig. 4 Intraocular pressure before and after the intravitreal administration of a MS 
suspensions of GDNF/VitE (■) and blank MSs (▲) in rabbits.  
 
Fig. 5 Semilog GDNF time-dependent concentration profiles in rabbit vitreous 
humour after the administration of MS suspensions of the GDNF/VitE formulation 
(■), and blank MS suspensions (▲). The green dashed line represents the average 
basal concentration of intravitreal GDNF in two eyes of one rabbit. (*) GDNF values 
under the detection limit (< 3.9 pg/mL). 
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Table 1. Experimental groups. 
 
Group 
N
o
 of 
rabbits 
Injection 
Time of 
enucleation 
Treatment 
N
o
 of eyes 
RE LE 
1 3 MSs 24 h GDNF-MSs Blank-MSs 6 
2 3 MSs 1 week GDNF-MSs Blank-MSs 6 
3 3 MSs 4 weeks GDNF-MSs Blank-MSs 6 
4 3 MSs 6 weeks GDNF-MSs Blank-MSs 6 
5 3 MSs 8 weeks GDNF-MSs Blank-MSs 6 
6 3 MSs 12 weeks GDNF-MSs Blank-MSs 6 
7 3 MSs 18 weeks GDNF-MSs Blank-MSs 6 
8 3 MSs 24 weeks GDNF-MSs Blank-MSs 6 
9 2 BSS 24 h BSS BSS 4 
Control 1 - - - - 2 
TOTAL 27     54 
 
Table 2: Pharmacokinetic parameters of GDNF distribution in the vitreous 
 
Pharmacokinetic parameter Non-compartment analysis 
Clapp(vitreous)/Fr (mL/day) 2.65 
AUC (pg·day/mL) 28238 
K01app (pg/day) 1973.4 
K02app (pg/day) 46.2 
t02 (day) > 42 
 
Clapp(vitreous), apparent vitreous clearance; AUC, area under the curve (0-168 
days); K01, zero-order release constant for 24 h to 4 weeks; K02, zero-order release 
constant for 8 to 24 weeks; T02, onset time of the stage 2.  
Note: Calculation of AUC value from blank microspheres group resulted 
meaningless so part of the experimental data were under the detection limit (< 3.9 
pg/mL) 
Note: Fr does not represent bioavailability (considered 100%) but the fraction of 
dose released during the 24 weeks assay. 
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